Frontlight ResearchEarly access
Lung cancer trials in Germany
163 of 182 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 3Not yet taking people in GermanyA Study of Ivonescimab Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC
- Where
- Bonn, Giessen, Luebeck, Munich
- Age
- 18 years and over
- People
- 183 worldwide
- Run by
- Summit Therapeutics Inc.
See details and how to join2026-526300-67-00 - Phase 3Taking peopleLUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- Where
- Berlin, Giessen, Halle, Heidelberg, Löwenstein, Oldenburg
- Age
- 18 years and over
- People
- 734 worldwide
- Run by
- NovoCure GmbH
See details and how to joinNCT06216301 - Phase 2/3Taking peopleA Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- Where
- Berlin, Dresden, Hamburg, Mannheim
- Age
- 18 years and over
- People
- 750 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT07365319 · EU 2025-525013-23-00 - Phase 3Not yet taking people in GermanyMK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
- Where
- Giessen, Hamburg, Luebeck
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07431827 · EU 2024-517337-41-00 - Phase 3Taking peopleA Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Where
- Berlin, Bochum, Essen, Gera, Grosshansdorf, Heidelberg, Mainz, Regensburg
- Age
- 18 years and over
- People
- 876 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07513376 · EU 2025-522643-18-00 - Phase 2Not yet taking people in GermanyAn international study evaluating diagnostic and theranostic agents in patients with solid tumors and brain metastases.
- Where
- Munich
- Age
- 18 years and over
- People
- 66 worldwide
- Run by
- Medica Scientia Innovation Research S.L.
See details and how to join2025-523824-39-01 - Phase 3Taking peopleA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Where
- Chemnitz, Gauting, Goettingen, Immenstadt I. Allgäu, Munich
- Age
- 18 years to 100 years
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00 - Phase 2Taking peopleSubstudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
- Where
- Berlin, Tuebingen
- Age
- 18 years and over
- People
- 144 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06780098 · EU 2024-518839-11-00 - Phase 2/3Taking peopleA Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Where
- Bonn, Donauwoerth, Essen, Goeppingen, Grosshansdorf, Hemer, Immenhausen, Loewenstein, Munich, Oldenburg, Regensburg, Stuttgart, Traunstein, Tuebingen, Ulm
- Age
- 18 years and over
- People
- 590 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00 - Phase 1/2Taking peopleA Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- Where
- Berlin, Dresden, Frankfurt Am Main, Freiburg im Breisgau, Goettingen, Heidelberg
- Age
- 18 years and over
- People
- 880 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07111520 · EU 2024-519344-32-00 - Phase 2Not yet taking people in GermanyA Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
- Where
- Chemnitz, Essen, Esslingen am Neckar, Munich
- Age
- 18 years and over
- People
- 105 worldwide
- Run by
- Verastem, Inc.
See details and how to joinNCT07659782 · EU 2026-526472-23-00 - Phase 1Active, not recruitingBeamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Where
- Augsburg, Cologne, Dresden, Giessen, Oldenburg
- Age
- 18 years and over
- People
- 554 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT04886804 · EU 2024-511246-39-00 - Phase 3Taking peopleA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Where
- Bielefeld, Greifswald, Solingen, Stuttgart
- Age
- 18 years and over
- People
- 348 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00 - Phase 3Taking peopleTrial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Where
- Aachen, Berlin, Bonn, Essen, Gauting, Großhansdorf, Halle, Heidelberg, Homburg, Kassel, München, Stuttgart
- Age
- 18 years and over
- People
- 363 worldwide
- Run by
- OSE Immunotherapeutics
See details and how to joinNCT06472245 - Phase 3Taking peopleThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Where
- Bad Berka, Berlin, Chemnitz, Cologne, Esslingen am Neckar, Gauting, Giessen, Grosshansdorf, Halle (saale), Kassel, Koblenz, Loewenstein, Luebeck, Oldenburg in Holstein, Traunstein, Treuenbrietzen, Ulm
- Age
- 18 years and over
- People
- 714 worldwide
- Run by
- Pfizer
See details and how to joinNCT06758401 · EU 2024-517968-36-00 - Phase 2/3Not yet taking people in GermanyStudy of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Where
- Berlin, Chemnitz, Cologne, Donauwörth, Esslingen am Neckar, Gauting, Hamburg, Heidelberg, Kassel, Kiel, Oldenburg, Stuttgart, Ulm
- Age
- 18 years and over
- People
- 661 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07100080 - Phase 3Not yet taking people in GermanyA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Where
- Bonn, Mainz, Stuttgart, Wuppertal
- Age
- 18 years and over
- People
- 675 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07190248 · EU 2024-514500-14-00 - Phase 3Taking peopleA Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- Where
- Essen, Freiburg im Breisgau, Giessen, Hamburg, Luebeck, Muenster
- Age
- 18 years and over
- People
- 310 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07554339 · EU 2025-522038-29-00 - Phase 3Not yet taking people in GermanyBL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
- Where
- Cologne, Essen, Halle
- Age
- 18 years and over
- People
- 550 worldwide
- Run by
- SystImmune Inc.
See details and how to joinNCT07625644 - Phase 1/2Taking peopleDAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Where
- Mainz, Stuttgart
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07707895 · EU 2026-525634-27-00 - Phase 4Active, not recruitingDabrafenib and/or Trametinib Rollover Study
- Where
- Augsburg, Essen, Hamburg, Heidelberg, Mannheim
- Age
- 18 years to 100 years
- People
- 100 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00 - Phase 3Taking peopleA Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Where
- Bad Berka, Berlin, Esslingen am Neckar, Gera, Halle (saale), Hemer, Koblenz, Leipzig, Regensburg
- Age
- 18 years and over
- People
- 780 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06312137 · EU 2023-508012-35-00 - Phase 3Taking peopleA Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Where
- Bad Berka, Cologne, Frankfurt am Main, Gauting, Grosshansdorf, Halle (Saale), Heidelberg, Oldenburg, Stuttgart
- Age
- 18 years and over
- People
- 530 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06646276 · EU 2024-515740-23-00 - Phase 3Taking peopleA Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
- Where
- Augsburg, Chemnitz, Esslingen am Neckar, Heidelberg, Immenhausen, Karlsruhe, Löwenstein, Lübeck, München, Nuremberg, Regensburg, Stuttgart
- Age
- 18 years and over
- People
- 420 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07099898 - Phase 3Taking peoplePhase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Where
- Bad Saarow, Bielefeld, Bonn, Cologne, Essen, Frankfurt am Main, Gauting, Hamburg, Heidelberg, Krefeld, Minden, Oldenburg, Stuttgart, Troisdorf, Velbert
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07291037 · EU 2024-520101-39-00